Catalyst Halts MarzAA Program for Hemophilia, Despite Positive Results

Catalyst Halts MarzAA Program for Hemophilia, Despite Positive Results

312177

Catalyst Halts MarzAA Program for Hemophilia, Despite Positive Results

In an unexpected turn, Catalyst Biosciences is discontinuing the clinical development of marzeptacog alfa activated (MarzAA), its experimental under-the-skin therapy for hemophilia A and B patients with inhibitors, which was being evaluated in an international Phase 3 clinical trial. “Based on several factors including a recently updated feasibility assessment, we determined that we cannot continue to develop MarzAA through completion of the ongoing trials” — notably the Phase 3 Crimson-1 trial (NCT04489537) and the Phase 1/2 MAA-202…

You must be logged in to read/download the full post.